As the first anti-obesity drug targeting multiple receptors, tirzepatide (Zepbound, Eli Lilly), a dual GIPR/GLP-1R agonist, was approved by the FDA in 2022
Here's what it doesn't mean: those results came from the FDA-approved Wegovy formulation in a controlled trial setting, with a specific patient population, a specific dosing protocol, and lifestyle intervention built in
ColonBroom emphasizes its non-GMO sourcing, vegan-friendly composition, and cGMP-certified manufacturing as a source of reassurance
By months eight through twelve, many people achieve a midsection they have not seen since their twenties, or in some cases, ever